Director, Cancer Dependency Map (DepMap), Broad Institute
Appears in 1 story
Accepted 2026 AACR Team Science Award on behalf of DepMap team; overseeing integration of resistance models into DepMap and ResMap
Every year, hundreds of thousands of lung cancer patients start treatment with osimertinib, the leading targeted therapy for tumors driven by mutations in the EGFR gene. Most will respond, but nearly all will eventually stop responding as their cancers evolve resistance through a dozen different molecular escape routes. Until now, researchers had to work with messy lab models that made it hard to pin down which genetic change caused which failure.
Updated May 31
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
